Surgery in Recurrent Ovarian Cancer: A Meta-Analysis.

Area of Science:

• Gynecologic Oncology
• Surgical Oncology
• Evidence-Based Medicine

Background:

• Recurrent ovarian cancer (ROC) treatment, particularly secondary cytoreductive surgery (SCS), remains a debated topic in oncology.
• Evaluating the efficacy of SCS combined with chemotherapy versus chemotherapy alone in patients with ROC is essential.

Purpose of the Study:

• To conduct a meta-analysis comparing overall survival (OS) and disease-free survival (DFS) for SCS plus chemotherapy versus chemotherapy alone in recurrent ovarian cancer patients.
• To assess the impact of complete versus incomplete cytoreduction on survival outcomes in ROC.

Main Methods:

• A systematic meta-analysis of randomized controlled trials (RCTs) was performed using PubMed and the Cochrane database.
• Three RCTs involving 1249 patients with recurrent ovarian cancer were included in the analysis.

Main Results:

• The meta-analysis revealed a significant improvement in OS (HR = 0.83, p < 0.04) and DFS (HR = 0.63, p < 0.000001) with SCS plus chemotherapy.
• Subgroup analysis showed that complete cytoreductive surgery significantly improved both OS (HR = 0.65, p = 0.002) and DFS (HR = 0.67, p = 0.0008) compared to surgery with residual tumor.

Conclusions:

• Complete secondary cytoreductive surgery (SCS) in recurrent ovarian cancer (ROC) significantly enhances overall survival (OS) and disease-free survival (DFS).
• The benefit of SCS is most pronounced when complete tumor removal is achieved.
• Optimal patient selection is critical for improving outcomes with secondary cytoreductive surgery in recurrent ovarian cancer.